Answers are grounded in this paper and cite their sources.
Prospective study reveals high diagnostic accuracy of photon-counting detector CT in breast cancer, suggesting its utility for simultaneous staging and tumor subtyping.
In this prospective study, we evaluated the performance of thoracoabdominal photon-counting detector computed tomography (PCD-CT) for breast cancer assessment with MRI as reference standard and iodine uptake as a potential marker for breast cancer subtyping. 75 women (mean age: 55.8 ± 13.9 years [SD]) with 79 newly diagnosed breast cancers and indication for staging CT received a prone-positioned contrast-enhanced thoracoabdominal PCD-CT and a breast MRI. Cancer visibility (median 1/1/1, IQR 0/1/1) and image quality (median 1/1/1, IQR 0/0/0) were rated excellent in PCD-CT on a 4-point Likert scale (1 = excellent, 4 = poor). Cancer size in PCD-CT correlated significantly with MRI (p < 0.001). Diagnostic accuracy was good for T-stage (pooled accuracy 0.814), focality (0.772), axillary (0.822) and internal mammary lymph nodes (0.981), moderate for ductal carcinoma in situ (0.591). A significantly lower maximum iodine uptake was revealed in cancer with ductal carcinoma in situ (p = 0.027), a significantly lower mean iodine uptake in triple negative cancers (p = 0.003). Thoracoabdominal PCD-CT demonstrated excellent cancer visibility with convincing results for assessing cancer size, T-stage, and lymph node status. Iodine uptake shows promising associations with triple negative breast cancer.
No takes yet. Share an insight, caveat, or question.
Neubauer et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: